The poor prognosis of lacrimal gland adenocarcinoma: a clinical study and literature review

被引:1
作者
Liu, Rui [1 ]
Ren, Tingting [1 ]
Li, Jing [1 ]
Wang, Nan [1 ]
Xu, Liangyuan [1 ]
Guo, Qihan [1 ]
Zhang, Hong [2 ]
Ma, Jianmin [1 ]
机构
[1] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing Tongren Eye Ctr, Beijing 100730, Peoples R China
[2] Capital Med Univ, Beijing Tongren Hosp, Pathol, Beijing 100730, Peoples R China
关键词
Adenocarcinoma; Ductal adenocarcinoma; Lacrimal gland; Prognosis; Treatment; PRIMARY DUCTAL ADENOCARCINOMA; ANDROGEN RECEPTOR; CARCINOMA;
D O I
10.1007/s00432-023-05510-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The incidence of lacrimal gland adenocarcinoma is low. This study was designed to analyze the clinical and prognostic characteristics of lacrimal gland adenocarcinoma. Methods This was a clinical study and literature review; 25 patients diagnosed with lacrimal gland adenocarcinoma by histopathology were enrolled and their medical history data were collected. Results The incidence of bone destruction and surrounding tissue invasion was 52% and 44%, respectively. The incidence of distant metastasis of lacrimal gland adenocarcinoma was about 50%. The 5-year overall survival rate of death or metastasis was 33.5%. Age, sex, laterality, tumor size, pathology type, bone destruction, nerve or perineural invasion, invasion of peripheral tissue, T stage, AR, Her-2 and treatment had no significant correlation with lacrimal adenocarcinoma's prognosis (P > 0.05), while the higher expression of Ki-67 may have higher risk of death or metastasis (P = 0.020). Conclusion The incidence of bone destruction and distant metastasis of lacrimal adenocarcinoma is high and the imaging examination is necessary to assess the risk of distant metastasis. The 5-year survival rate of death or metastasis is 33.5% and the high expression of Ki-67 predicts poor prognosis of lacrimal adenocarcinoma.
引用
收藏
页数:9
相关论文
共 33 条
  • [1] Alkatan H, 2018, WHO classification of tumours of the eye
  • [2] Lacrimal gland ductal carcinomas: Clinical, Morphological and Genetic characterization and implications for targeted treatment
    Andreasen, Simon
    Grauslund, Morten
    Heegaard, Steffen
    [J]. ACTA OPHTHALMOLOGICA, 2017, 95 (03) : 299 - 306
  • [3] Epidemiological Trends in Malignant Lacrimal Gland Tumors
    Andreoli, Michael T.
    Aakalu, Vinay
    Setabutr, Pete
    [J]. OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2015, 152 (02) : 279 - 283
  • [4] Androgen Receptor in Breast Cancer-Clinical and Preclinical Research Insights
    Anestis, Aristomenis
    Zoi, Ilianna
    Papavassiliou, Athanasios G.
    Karamouzis, Michalis V.
    [J]. MOLECULES, 2020, 25 (02):
  • [5] Lacrimal gland adenocarcinoma responding to checkpoint inhibition and androgen deprivation
    Bulbul, Ajaz
    [J]. OXFORD MEDICAL CASE REPORTS, 2018, (09): : 290 - 292
  • [6] Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
    Dennie, Trevor
    [J]. CASE REPORTS IN ONCOLOGICAL MEDICINE, 2015, 2015
  • [7] Fakhril-Din Zainab, 2023, Am J Ophthalmol Case Rep, V31, P101855, DOI 10.1016/j.ajoc.2023.101855
  • [8] Primary ductal adenocarcinoma of the lacrimal gland: case report
    Ferreira Damasceno, Renato Wendell
    Holbach, Leonard M.
    [J]. ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2012, 75 (01) : 64 - 66
  • [9] Intracapsular High-Grade Ductal Carcinoma In-Situ Ex Pleomorphic Adenoma of the Lacrimal Gland
    Garakani, Roya
    Kersten, Robert
    Pekmezci, Melike
    [J]. OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2020, 36 (01) : E1 - E3
  • [10] Clinico-epidemiological analysis of 1000 cases of orbital tumors
    Goto, Hiroshi
    Yamakawa, Naoyuki
    Komatsu, Hiroyuki
    Asakage, Masaki
    Tsubota, Kinya
    Ueda, Shun-ichiro
    Nemoto, Rei
    Umazume, Kazuhiko
    Usui, Yoshihiko
    Mori, Hideki
    [J]. JAPANESE JOURNAL OF OPHTHALMOLOGY, 2021, 65 (05) : 704 - 723